EDDING GENOR (06998) has announced that the first patient has been dosed in a Phase II clinical trial for its innovative small nucleic acid drug, EDP167. The Phase II trial is a multicenter, dose-exploration, open-label study focusing on adult patients with homozygous familial hypercholesterolemia (HoFH). The study is designed to assess the efficacy and safety of EDP167 in HoFH patients, with the primary endpoint being the change in low-density lipoprotein cholesterol (LDL-C) levels from the baseline after 24 weeks following the initial dose. Evaluation of the primary endpoint is anticipated to be completed in the fourth quarter of 2026.